Evaluation of Ocoxin®-Viusid® in Breast Cancer

NCT03576521 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Breast Carcinoma
Adriamycin Toxicity
Cyclosporine Toxicity

Interventions

COMBINATION_PRODUCT: CT + Ocoxin-Viusid
COMBINATION_PRODUCT: CT + Placebo

Sponsor

Catalysis SL